Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
12.33
-0.17 (-1.36%)
At close: Feb 19, 2026, 4:00 PM EST
12.43
+0.10 (0.81%)
After-hours: Feb 19, 2026, 4:10 PM EST
Tenax Therapeutics Employees
As of December 31, 2024, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,221,000
Market Cap
500.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Lyell Immunopharma | 300 |
| ADC Therapeutics | 265 |
| Allogene Therapeutics | 229 |
| Prothena Corporation | 163 |
| Vor Biopharma | 154 |
| Gossamer Bio | 145 |
| Ocugen | 95 |
TENX News
- 15 days ago - Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewsWire
- 5 weeks ago - Tenax Therapeutics: A Speculative Buy - Seeking Alpha
- 6 weeks ago - Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
- 2 months ago - Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha
- 3 months ago - Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - GlobeNewsWire